Evaluation of In-vitro Bioequivalence of Commonly Prescribed Generics of Poorly Water Soluble Drug-Atorvastatin Calcium in Pakistan
暂无分享,去创建一个
Atorvastatin is a HMG-CoA reductase inhibitor which reduces the blood cholesterol levels and is commonly used for the treatment of hypertension. It is a poorly water soluble drug and has 14% oral bioavailability therefore mild formulation factors may affect its oral absorption and bioavailability. This study was aimed to conduct bioequivalence study for six commonly prescribed brands of atorvastatin. In this study in vitro bioavailability of six generic brands of atorvastatin were compared with the standard brand leader using their dissolution profiles and evaluation of pharmacokinetic data model independent approach (f1 and f2). Only one generic brand exhibits similar release profile and its f1 and f2 values were within range and the rest of the five brands did not show similar release patterns in comparison to the brand leader. The results of other physical test were found to be within range. It is concluded that all generic brands of atorvastatin are not bioequivalent in terms of their in vitro release behavior. Thus in vitro testing should be declared as mandatory requirement for registration of any pharmaceutical generic in Pakistan.
[1] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[2] D. Hunninghake,et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.
[3] H. Lennernäs. Clinical Pharmacokinetics of Atorvastatin , 2003, Clinical pharmacokinetics.